- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00373113
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, C1405BCH
- Pfizer Investigational Site
-
Buenos Aires, Argentinien, C1034ACO
- Pfizer Investigational Site
-
Cordoba, Argentinien, X5000AAI
- Pfizer Investigational Site
-
Tucuman, Argentinien, T4000IAK
- Pfizer Investigational Site
-
-
Prov. de Buenos Aires
-
Bahia Blanca, Prov. de Buenos Aires, Argentinien, B8001HXM
- Pfizer Investigational Site
-
-
Rio Negro
-
Viedma, Rio Negro, Argentinien, 8500
- Pfizer Investigational Site
-
-
Santa Fé
-
Rosario, Santa Fé, Argentinien, (2000)
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australien, 2010
- Pfizer Investigational Site
-
-
Queensland
-
Herston, Queensland, Australien, 4029
- Pfizer Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Pfizer Investigational Site
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Pfizer Investigational Site
-
Parkville, Victoria, Australien, 3050
- Pfizer Investigational Site
-
-
Western Australia
-
Perth, Western Australia, Australien, 6000
- Pfizer Investigational Site
-
-
-
-
PR
-
Curitiba, PR, Brasilien, 80530-010
- Pfizer Investigational Site
-
-
RJ
-
Rio de Janeiro, RJ, Brasilien, 20560-120
- Pfizer Investigational Site
-
-
RS
-
Porto Alegre, RS, Brasilien, 90610-000
- Pfizer Investigational Site
-
Porto Alegre, RS, Brasilien, 91350-200
- Pfizer Investigational Site
-
-
SP
-
São Paulo, SP, Brasilien, 01509-900
- Pfizer Investigational Site
-
São Paulo, SP, Brasilien, 01246-000
- Pfizer Investigational Site
-
-
-
-
-
Sofia, Bulgarien, 1233
- Pfizer Investigational Site
-
Sofia, Bulgarien, 1527
- Pfizer Investigational Site
-
Sofia, Bulgarien, 1756
- Pfizer Investigational Site
-
Stara Zagora, Bulgarien, 6000
- Pfizer Investigational Site
-
-
-
-
IX Región
-
Temuco, IX Región, Chile, 4810469
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Deutschland, 12200
- Pfizer Investigational Site
-
Frankfurt, Deutschland, 60488
- Pfizer Investigational Site
-
Freiburg, Deutschland, 79106
- Pfizer Investigational Site
-
Jena, Deutschland, 07743
- Pfizer Investigational Site
-
Kiel, Deutschland, 24103
- Pfizer Investigational Site
-
Leer, Deutschland, 26789
- Pfizer Investigational Site
-
Luebeck, Deutschland, 23538
- Pfizer Investigational Site
-
Magdeburg, Deutschland, 39130
- Pfizer Investigational Site
-
Mainz, Deutschland, 55101
- Pfizer Investigational Site
-
Meiningen, Deutschland, 98617
- Pfizer Investigational Site
-
Muenchen, Deutschland, 81675
- Pfizer Investigational Site
-
Offenburg, Deutschland, 77652
- Pfizer Investigational Site
-
Tuebingen, Deutschland, 72076
- Pfizer Investigational Site
-
-
-
-
-
Bayonne, Frankreich, 64100
- Pfizer Investigational Site
-
Besancon, Frankreich, 25030
- Pfizer Investigational Site
-
Clermont Ferrand, Frankreich, 63011
- Pfizer Investigational Site
-
Lille, Frankreich, 59020 Cedex
- Pfizer Investigational Site
-
Neuilly Sur Seine, Frankreich, 92200
- Pfizer Investigational Site
-
Nice, Frankreich, 06100
- Pfizer Investigational Site
-
Rennes Cedex, Frankreich, 35042
- Pfizer Investigational Site
-
-
-
-
-
Hong Kong, Hongkong
- Pfizer Investigational Site
-
Kowloon, Hongkong
- Pfizer Investigational Site
-
Tuen Mun, Hongkong
- Pfizer Investigational Site
-
Wan Chai,, Hongkong
- Pfizer Investigational Site
-
-
-
-
Gujarat
-
Navrangpura / Ahmedabad, Gujarat, Indien, 380 009
- Pfizer Investigational Site
-
-
Karnataka
-
Bangalore, Karnataka, Indien, 560 078
- Pfizer Investigational Site
-
-
Punjab
-
Ludhiana, Punjab, Indien, 141 008
- Pfizer Investigational Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302013
- Pfizer Investigational Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Indien, 226003
- Pfizer Investigational Site
-
-
-
-
-
Firenze, Italien, 50134
- Pfizer Investigational Site
-
Milano, Italien, 20162
- Pfizer Investigational Site
-
Napoli, Italien, 80131
- Pfizer Investigational Site
-
Reggio Emilia, Italien, 42100
- Pfizer Investigational Site
-
-
-
-
-
Fukuoka, Japan
- Pfizer Investigational Site
-
Osaka, Japan
- Pfizer Investigational Site
-
-
Aichi
-
Nagoya, Aichi, Japan
- Pfizer Investigational Site
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan
- Pfizer Investigational Site
-
-
Fukuoka
-
Kitakyushu-City, Fukuoka, Japan
- Pfizer Investigational Site
-
-
Osaka
-
Suita, Osaka, Japan
- Pfizer Investigational Site
-
-
Saitama
-
Kita-adachi-gun, Saitama, Japan
- Pfizer Investigational Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Chuo-Ku, Tokyo, Japan
- Pfizer Investigational Site
-
-
-
-
-
Quebec, Kanada, G1S 4L8
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, Kanada, B3H 3A7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, Kanada, B3H 2Y9
- Pfizer Investigational Site
-
-
Ontario
-
London, Ontario, Kanada, N6A 4L6
- Pfizer Investigational Site
-
Toronto, Ontario, Kanada, M4N 3M5
- Pfizer Investigational Site
-
-
-
-
Antioquia
-
Medellin, Antioquia, Kolumbien
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Kolumbien
- Pfizer Investigational Site
-
-
-
-
-
Daegu, Korea, Republik von, 705-717
- Pfizer Investigational Site
-
Incheon, Korea, Republik von, 400-711
- Pfizer Investigational Site
-
Pusan, Korea, Republik von, 602-739
- Pfizer Investigational Site
-
Seoul, Korea, Republik von, 110-744
- Pfizer Investigational Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republik von, 410-769
- Pfizer Investigational Site
-
-
-
-
-
Chihuahua, Mexiko, 31000
- Pfizer Investigational Site
-
Puebla, Mexiko, 72530
- Pfizer Investigational Site
-
-
DF
-
Mexico, DF, Mexiko, 11000
- Pfizer Investigational Site
-
-
Estado de Mexico
-
Toluca, Estado de Mexico, Mexiko, 50180
- Pfizer Investigational Site
-
-
Guerrero
-
Acapulco, Guerrero, Mexiko, 39670
- Pfizer Investigational Site
-
-
Michoacan
-
Morelia, Michoacan, Mexiko, 58020
- Pfizer Investigational Site
-
-
Sonora
-
Ciudad Obregon, Sonora, Mexiko, 85000
- Pfizer Investigational Site
-
-
-
-
-
Lima, Peru, 05127
- Pfizer Investigational Site
-
Lima, Peru, L 27
- Pfizer Investigational Site
-
-
-
-
-
Quezon City, Philippinen, 1100
- Pfizer Investigational Site
-
Quezon City, Philippinen, 1102
- Pfizer Investigational Site
-
Quezon City, Philippinen, 1104
- Pfizer Investigational Site
-
San Juan City, Philippinen, 1000
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapur, 119074
- Pfizer Investigational Site
-
Singapore, Singapur, 169610
- Pfizer Investigational Site
-
-
-
-
-
Cordoba, Spanien, 14004
- Pfizer Investigational Site
-
Gerona, Spanien, 17007
- Pfizer Investigational Site
-
Jaen, Spanien, 23007
- Pfizer Investigational Site
-
La Coruña, Spanien, 15006
- Pfizer Investigational Site
-
Las Palmas de Gran Canaria, Spanien, 35016
- Pfizer Investigational Site
-
Madrid, Spanien, 28040
- Pfizer Investigational Site
-
Madrid, Spanien, 28033
- Pfizer Investigational Site
-
Malaga, Spanien, 29010
- Pfizer Investigational Site
-
Salamanca, Spanien, 37007
- Pfizer Investigational Site
-
-
Barcelona
-
Mataro, Barcelona, Spanien, 08304
- Pfizer Investigational Site
-
Sabadell, Barcelona, Spanien, 08208
- Pfizer Investigational Site
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Pfizer Investigational Site
-
-
Madrid
-
Alcorcon, Madrid, Spanien, 28922
- Pfizer Investigational Site
-
-
Vizcaya
-
Bilbao, Vizcaya, Spanien, 48013
- Pfizer Investigational Site
-
-
-
-
-
Parktown, Südafrika, 2193
- Pfizer Investigational Site
-
Sandton, Südafrika, 2199
- Pfizer Investigational Site
-
-
-
-
-
Changhua, Taiwan, 500
- Pfizer Investigational Site
-
Kaohsiung, Taiwan, 807
- Pfizer Investigational Site
-
Tainan, Taiwan, 704
- Pfizer Investigational Site
-
Taipei, Taiwan, 100
- Pfizer Investigational Site
-
Taipei, Taiwan, 112
- Pfizer Investigational Site
-
Taipei, Taiwan, 106
- Pfizer Investigational Site
-
Taoyuan, Taiwan, 333
- Pfizer Investigational Site
-
-
-
-
-
Ankara, Truthahn, 06100
- Pfizer Investigational Site
-
Istanbul, Truthahn, 34390
- Pfizer Investigational Site
-
-
-
-
-
London, Vereinigtes Königreich, SE1 9RT
- Pfizer Investigational Site
-
Nottingham, Vereinigtes Königreich, NG5 1PB
- Pfizer Investigational Site
-
Somerset, Vereinigtes Königreich, BA21 4AT
- Pfizer Investigational Site
-
-
South Wales
-
Cardiff, South Wales, Vereinigtes Königreich, CF14 2TL
- Pfizer Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- breast adenocarcinoma
- prior treatment with an anthracycline and a taxane either concurrently or sequentially in the neoadjuvant, adjuvant and or/ advanced disease treatment settings. No more than 1 chemotherapy regimen in the advanced setting
Exclusion Criteria:
- Prior treatment with regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines and taxanes or multiple anthracyclines/ taxanes treatments.
- Any prior regimen with capecitabine
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: A
1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
|
1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Andere Namen:
|
Experimental: B
37.5 mg daily, continuous dosing
|
37.5 mg daily, continuous dosing
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-Free Survival (PFS)
Zeitfenster: From time of randomization to every 6 weeks thereafter through 22 months or until death
|
Time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occured first.
|
From time of randomization to every 6 weeks thereafter through 22 months or until death
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Time to Tumor Progression (TTP)
Zeitfenster: From time of randomization to every 6 weeks thereafter through 22 months
|
Time from randomization to first documentation of objective tumor progression.
|
From time of randomization to every 6 weeks thereafter through 22 months
|
Number of Participants With Overall Response (OR)
Zeitfenster: From time of randomization to every 6 weeks thereafter through 22 months
|
OR was defined as the number of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.0) for at least 4 weeks, confirmed by repeat tumor assessments.
CR was defined as the disappearance of all target lesions.
PR was defined as a greater than or equal to (>=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
|
From time of randomization to every 6 weeks thereafter through 22 months
|
Duration of Response (DR)
Zeitfenster: From time of randomization to every 6 weeks thereafter through 22 months or death
|
Time from the first documentation of OR (CR or PR) that was subsequently confirmed to the first documentation of tumor progression or death due to any cause.
CR was defined as disappearance of all target lesions.
PR was defined as a >= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.
|
From time of randomization to every 6 weeks thereafter through 22 months or death
|
Time to Tumor Response (TTR)
Zeitfenster: From time of randomization to every 6 weeks thereafter through 22 months
|
Time from randomization to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.
CR was defined as disappearance of all target lesions.
PR was defined as a >= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.
|
From time of randomization to every 6 weeks thereafter through 22 months
|
Overall Survival (OS)
Zeitfenster: From time of randomization until death
|
Average time from randomization to first documentation of death due to any cause.
|
From time of randomization until death
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)
Zeitfenster: From Day 1 of Cycle 1, then odd numbered cycles thereafter
|
EORTC QLQ-C30 scales: functional (physical/role/cognitive/emotional/social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea). Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms. |
From Day 1 of Cycle 1, then odd numbered cycles thereafter
|
EORTC QLQ Breast Cancer Module (BR23)
Zeitfenster: From Day 1 of Cycle 1, then odd numbered cycles thereafter
|
BR23: measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score implied a greater degree of symptoms. |
From Day 1 of Cycle 1, then odd numbered cycles thereafter
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Hautkrankheiten
- Neubildungen
- Neubildungen nach Standort
- Brusterkrankungen
- Neoplasien der Brust
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Proteinkinase-Inhibitoren
- Capecitabin
- Sunitinib
Andere Studien-ID-Nummern
- A6181107
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Neoplasien der Brust
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada
Klinische Studien zur Capecitabine
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNoch keine RekrutierungNeoplasien der Brust | Lokal fortgeschrittener oder metastasierter BrustkrebsChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRekrutierung
-
Hoffmann-La RocheAbgeschlossenBrustkrebs, DarmkrebsNeuseeland, Australien, Vereinigtes Königreich
-
Samsung Medical CenterAbgeschlossenFortgeschrittenes oder rezidivierendes Plattenepithelkarzinom des ÖsophagusKorea, Republik von
-
Jiangxi Provincial Cancer HospitalNoch keine RekrutierungNasopharynxkarzinom | Erhaltungstherapie | Krebs mit hohem Risiko
-
Jules Bordet InstituteAbgeschlossenBrustkrebs | Ältere PatientenBelgien
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnbekanntKarzinom, invasives Duktalkarzinom, BrustChina
-
Binghe XuHoffmann-La RocheUnbekanntHautkrankheiten | Neubildungen nach Standort | Neoplasien der Brust | Brusterkrankungen | Neoplasma MetastasierungChina
-
The First Affiliated Hospital of Zhengzhou UniversityRekrutierung
-
Hebei Medical UniversityAbgeschlossenAdenokarzinom des gastroösophagealen ÜbergangesChina